Immunosuppression status of liver transplant recipients with hepatitis C affects biopsy-proven acute rejection.
- Author:
Jong Man KIM
1
;
Kwang Woong LEE
;
Gi Won SONG
;
Bo Hyun JUNG
;
Hae Won LEE
;
Nam Joon YI
;
ChoonHyuck David KWON
;
Shin HWANG
;
Kyung Suk SUH
;
Jae Won JOH
;
Suk Koo LEE
;
Sung Gyu LEE
Author Information
- Publication Type:Original Article
- Keywords: Hepatitis C virus; Immunosuppression; Rejection; Outcome; Calcineurin antagonists; Tacrolimus
- MeSH: Antibodies, Monoclonal/therapeutic use; Biopsy; Cyclosporine/therapeutic use; Drug Therapy, Combination; Genotype; Graft Rejection/mortality/*prevention & control; Hepacivirus/genetics/isolation & purification; Hepatitis C/drug therapy/*virology; Humans; Immunosuppressive Agents/*therapeutic use; *Liver Transplantation/adverse effects; Polymerase Chain Reaction; RNA, Viral/blood; Recombinant Fusion Proteins/therapeutic use; Recurrence; Retrospective Studies; Survival Rate; Tacrolimus/therapeutic use
- From:Clinical and Molecular Hepatology 2016;22(3):366-371
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND/AIMS: The relationship between patient survival and biopsy-proven acute rejection (BPAR) in liver transplant recipients with hepatitis C remains unclear. The aims of this study were to compare the characteristics of patients with and without BPAR and to identify risk factors for BPAR. METHODS: We retrospectively reviewed the records of 169 HCV-RNA-positive patients who underwent LT at three centers. RESULTS: BPAR occurred in 39 (23.1%) of the HCV-RNA-positive recipients after LT. The 1-, 3-, and 5-year survival rates were 92.1%, 90.3%, and 88.5%, respectively, in patients without BPAR, and 75.7%, 63.4%, and 58.9% in patients with BPAR (P<0.001). Multivariate analyses showed that BPAR was associated with the non-use of basiliximab and tacrolimus and the use of cyclosporin in LT recipients with HCV RNA-positive. CONCLUSION: The results of the present study suggest that the immunosuppression status of HCV-RNA-positive LT recipients should be carefully determined in order to prevent BPAR and to improve patient survival.
